TY027 / Tychan - LARVOL DELTA

Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans (clinicaltrials.gov) - P3 | N=17 | Terminated | Sponsor: Tychan Pte Ltd. | N=1305 ➔ 17 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2021 ➔ Mar 2022; Low recruitment rate

Enrollment change • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Scientific Journal Antiviral Research Publishes Study Demonstrating Benefits of Tychan’s Antibody Discovery Technology Platform (Businesswire) - "Tychan...announced the publication of a scientific study highlighting key advantages of its innovative antibody discovery technology platform that it created for rapid development of novel therapeutics to target infectious diseases, including yellow fever, Zika, and COVID-19....TY027, a novel therapeutic mAb targeting SARS-Cov-2, targets a highly conserved region of the viral spike protein. TY027, one of the earliest mAbs to obtain IND approval globally, is currently in Phase-3 trials in Singapore and is active against all of the variant strains of the virus now circulating, including the recent delta variant."

Preclinical • Review • Infectious Disease • Novel Coronavirus Disease

Safety of TY027, a Treatment for COVID-19, in Humans (clinicaltrials.gov) - P1; N=32; Completed; Sponsor: Tychan Pte Ltd.; Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans (clinicaltrials.gov) - P3; N=1305; Recruiting; Sponsor: Tychan Pte Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

Tychan to Start COVID-19 Phase 3 Clinical Trial For Novel Monoclonal Antibody TY027 (Businesswire) - P1, N=32; NCT04429529; Sponsor: Tychan Pte Ltd.; "Results of Phase 1 clinical trials showed no serious adverse events with infusion of TY027 in healthy volunteers, and researchers evaluated up to the 30 mg/kg dose....The Phase 3 clinical trial is the final phase of trials for TY027 and will involve 1,305 volunteer COVID-19-positive patients from partner hospitals....Phase 3 clinical trial for TY027 will also take place in partner hospitals overseas, such as Sheba Medical Centre in Israel....'We are pleased that the Phase 3 clinical trial can now start in partnership with Sheba Medical Centre, while we continue to explore collaborations with other medical facilities in countries where COVID-19 incidence remains high'."

New P3 trial • P1 data • Infectious Disease • Novel Coronavirus Disease

Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans (clinicaltrials.gov) - P3; N=1305; Not yet recruiting; Sponsor: Tychan Pte Ltd.

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

Phase update (clinicaltrials.gov) - P1➔P2, Novel Coronavirus Disease

Phase shift • Novel Coronavirus Disease

Safety of TY027, a Treatment for COVID-19, in Humans (clinicaltrials.gov) - P1; N=32; Active, not recruiting; Sponsor: Tychan Pte Ltd.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Tychan to begin first clinical trials for first novel monoclonal antibody against Covid-19 (PipelineReview) - "Tychan...is initiating Phase 1 clinical trials to evaluate TY027, the first novel monoclonal antibody (mAb) that specifically targets SARS-CoV-2....The trial is expected to take only about six weeks....Approved by the Singapore regulatory agency, Health Sciences Authority, the Phase 1 trial will be conducted by SingHealth Investigational Medicine Unit....Efficacy data is expected to be available in the third quarter of this year."

New P1 trial • P1 data • Infectious Disease • Novel Coronavirus Disease

Safety of TY027, a Treatment for COVID-19, in Humans (clinicaltrials.gov) - P1; N=25; Recruiting; Sponsor: Tychan Pte Ltd.

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease